Background: Pulmonary sarcomatoid carcinoma (SC) is a rare disease with poor prognosis and with strong inter-and intratumor heterogeneity. However, molecular classification is currently focused on activating MET mutations. We sought to better characterize the molecular diversity of SC using mutational signatures that reflect different mutational processes, such as tobacco-associated adducts (signature 4), BRCA1/BRCA2 deficiency (signature 3), or APOBEC enzyme deamination (signatures 2 and 13).
Introduction
Pulmonary sarcomatoid carcinoma (SC) is a rare disease associated with heavy smoking and poor prognosis [1, 2] . Pleomorphic, spindle cell and giant cell carcinoma are the more frequent subtypes among this entity. It features a sarcoma-like element (i.e. spindle or giant cells) associated with an epithelial component (i.e. adenocarcinoma, squamous carcinoma, or poorly differentiated large-cell carcinoma) [3] . SC is highly chemoresistant to platinum-based regimens, with disease progression reported in two-thirds of patients on first evaluation [4, 5] . Recent studies in SC have discovered a high incidence of MET exon 14 mutations and MET amplifications indicating a specific genetic feature of this disease [6, 7] . In addition, a large diversity of alterations have been reported including TP53, EGFR, KRAS, PIK3CA, and STK11 mutations, ALK translocations, ALK, EGFR, CDK4, and MDM2 amplifications [6] [7] [8] [9] . The low incidence, complexity, and heterogeneity of this disease could explain our limited knowledge of its specific biology [10] .
Molecular classification of cancers has afforded us better understanding of the biology of many diseases. The recent description of mutational signatures is a new opportunity for tumor classification [11] . Using next-generation sequencing (NGS), Alexandrov et al. recently analyzed the pattern of somatic mutations in a tri-nucleotide context, identifying 18 mutational signatures, since enlarged to 30 [12] . These are associated with specific mutational processes, such as smoking (signature 4), homologous repair deficiency (signature 3), and APOBEC activation (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like, signatures 2 and 13) [12] .
In order to better characterize SC biology, we carried out whole-exome sequencing (WES) in a series of 15 resected tumors, in addition to analyzing 10 previously published cases [7] . Molecular classification was based on mutational signatures, defining two clusters: C sig4 characterized by signature 4, indicating a direct effect of tobacco on DNA, associated with frequent RAS/MAP2K1 mutations and strong PD-L1 expression; C sig2-3-13 with mutagenesis related to APOBEC and homologous repair deficiency, associated with not only MET yet also EGFR, BRCA1/ BRCA2, and IDH1 alterations.
Materials and methods

Study design and population
The study was reviewed and approved by our assigned ethics committee (CPP Ile-de-France II n 2016-10-10). Our research was conducted with accordance to the Helsinki Declaration. We included 10 men and 5 women, all smokers. These patients underwent thoracic surgery in a curative intent. All specimens were locally reviewed according to the World Health Organization's 2015 classification (MA) [3] . Histological subtypes were pure giant cells (n ¼ 1) or pleomorphic carcinomas (n ¼ 14/15), with the sarcomatoid component composed of spindle cells (n ¼ 5), giant cells (n ¼ 4), or mixed (n ¼ 6); and the epithelial component of adenocarcinoma (n ¼ 4), squamous carcinoma (n ¼ 3), large cells (n ¼ 1), or mixed (n ¼ 6). The sarcomatoid component accounted for 10%-90% of tumor cells.
WES and analysis
WES was carried out on frozen tumor samples and matched normal tissues. The sequencing and bioinformatic methods are detailed in the Appendix (online only).
Mutation validation using targeted NGS
For the orthogonal confirmation of mutations detected using WES, samples were sequenced using the IonAmpliSeq TM Hotspot Cancer Panel (Thermofisher). Libraries were sequenced using the Ion Chief TM and Ion Proton TM systems.
Copy number analysis and clonality
Genome segmentation, copy number estimates, and ploidy were obtained using Sequenza with default parameters [13] . The frequencies of gains and losses were plotted using R, with thresholds for copy number/ploidy ratios of À0.4, 0.4, and 1.7 for losses, gains, and amplification, respectively. The copy number profiles of all samples were analyzed using GISTIC2 with log2ratio thresholds of 0.1 and À0.1 for gains and losses, respectively [14] . A q-value threshold of 0.25 was applied to select significant peaks. Clonality was estimated using ABSOLUTE [15] and THetA2 [16] with default parameters.
Public sequencing data from Liu et al
The mutations annotations from Liu et al. were obtained from supplementary data, available at Annals of Oncology online [7] . Variants were selected using these filters: >1 read in positive or negative strand supporting variant, or a P-value for base quality bias <0.05, or a P-value mapping quality bias <0.05, or a P-value for tail-distance bias <0.05. Variants with allele frequencies >0.1% in 1000Genome or the Exome Sequencing Project were excluded. From an initial 1434 variants in the 10 samples, 1195 were selected.
Mutational signatures
Mutational signatures described by Alexandrov et al. [17] and curated at http://cancer.sanger.ac.uk/cosmic/signatures were evaluated using DeconstructSig [18] with following parameters: 'exome2genome' trinucleotide-count normalization and signature cutoff at 6%. Hierarchical and non-negative matrix factorization (NMF) methods for clustering based on mutational signatures are described in the supplementary methods, available at Annals of Oncology online.
Replication and transcriptional asymmetries
Transcriptional direction and replication direction were obtained from previous studies [19, 20] . Mutational densities were calculated for each base pair change and each sample cluster (C sig4 and C sig2-3-13 ). Log2 ratios of complementary nucleotide changes (A>C/T>G, A>G/T>C, A>T/T>A, C>A/G>T, C>G/G>C, C>T/G>A) were computed as described by Haradhvala et al. [20] , plotted in supplementary Figure S1 , available at Annals of Oncology online. The global mutational asymmetries for transcription and replication were computed as previously described and plotted in Figure 2 .
Silver in situ hybridization and immunohistochemistry
MET silver in situ hybridization (SISH), c-Met immunohistochemistry (IHC), and PD-L1 IHC are described in the supplementary methods, available at Annals of Oncology online.
Results
Intertumor molecular variability
Mutational signature profiles in pulmonary SC. We sought to decipher the heterogeneity of SC by performing WES on 15 samples (supplementary Table S1 , available at Annals of Oncology online), first characterizing the mutational signatures described by Alexandrov et al. We found high variability between samples ( Figure 1A) , with signature 4 being the predominant signature in a SC subgroup only. We applied two different clustering methods that identified two robust cluster groups based on different mutational signatures (Figure 1B-D; supplementary Figure S1 , available at Annals of Oncology online). C sig4 (n ¼ 9) was characterized by the tobacco-related signature 4 and signatures 8 and 25. C sig2-3-13 (n ¼ 6) was characterized by the presence of mutational signatures 2 and 13, related to the activation of apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC), and signature 3, linked to homologous recombination deficiency. Confirmation of different tobacco-related and APOBEC-related mutations. To confirm that the mutational processes in C sig4 differed from those in C sig2-3-13 , we applied a method developed by Haradhvala et al. [20] , quantifying the somatic mutation burden in a group of tumor samples linked to a transcription or replication defect, enabling detection of the dominant mutational mechanisms of a group of samples. APOBEC-related mutagenesis was confirmed in C sig2-3-13 by a strong replication asymmetry of C!G and C!T mutations ( Figure 1E ; supplementary Figure S2 , available at Annals of Oncology online). In contrast, a transcription asymmetry reflecting exposure to tobacco smoke was found in C sig4 and, to a lesser extent, in C sig2-3-13 , confirming tobacco exposure in both groups.
Signature in clonal and subclonal mutations. The mutational signatures were estimated separately on clonal mutations, which reflect the early mutagenesis, and on subclonal mutations, which reflect the later mutagenesis (supplementary Figure S3 , available at Annals of Oncology online). In C sig2-3-13 , signatures 2 and 13 were present in similar quantities in both clonal and subclonal mutations ( Figure 1F and I). The same was found for signature 3 ( Figure 1G ). In contrast, in C sig4 , signature 4 was more abundant in the clonal mutations than the subclonal mutations (P ¼ 0.005, Figure 1H ). These results suggest tobacco smoking contributes to causing C sig4 -type SC, as well as the initiator and persisting role of APOBEC and homologous repair in mutagenesis, throughout the tumor evolution in C sig2-3-13 -type SC.
Validation of SC clustering in an independent series. We reanalyzed the 10 WES of SC published by Liu et al. [7] and carried out similar mutational signature and clustering analyses ( Figure 1J-L) . In this series, the group with signature 4 was smaller than our series. Due to the smaller sample size, the clusters were instable between the two clustering methods, yet both clearly distinguished two clusters (supplementary Figure S4 , available at Annals of Oncology online), one with signature 4, the other with signatures 3 and 13. It was also possible to isolate a third cluster of two samples presenting signature 16 as the predominant signature (supplementary Figure S4 , available at Annals of Oncology online). Signature 16 has recently been implicated in some tobacco-exposed patients, though its underlying mutational process is as yet unknown [21] . Finally, we carried out clustering analyses on the pooled series ( Figure 1M -O) to further clarify our findings, confirming two clusters that were consistent in both clustering methods (supplementary Figure S5 , available at Annals of Oncology online); C sig4 and C sig2-3-13 .
Alterations associated with the two SC clusters. The previous clustering analysis suggests the existence of two SC groups associated with different mutational signatures. By pooling our series with that of Liu et al. [7] , we observed that MET alterations were identified in five of the 11 C sig2-3-13 -type SC cases, compared with none of the 14 C sig4 SC (P ¼ 0.009, Fisher's exact test) ( Figure  2A ). Apart from MET, other druggable alterations were detected only in C sig2-3-13 : EGFR mutation (p.G719A); IDH1 mutation (p.R132H); AKT3 amplification; BRCA1 alterations (p.T582R þ LOH); BRCA2 alterations (p.K82* þ LOH); and BRCA2 alterations (p.S3149R þ LOH). In contrast, mutations of RAS genes were significantly more frequent in the C sig4 versus C sig2-3-13 (10/14 versus 2/11, respectively, P ¼ 0.02).
We then compared the frequencies of the recurrent copy number aberrations between C sig4 and C sig2-3-13 ( Figure 2E ; supplementary Figure S6A and B, available at Annals of Oncology online). We found four regions gained in both clusters (1q32.1-IGFN1, 3q29-MUC4, 7q34-PRSS1, and Xp22.33-GYG2). Five regions were more frequently gained in C sig4 versus C sig2-3-13 (6p21.32-HLA-DQA2 and HLA-DQB2, 11p15.5-MUC2 and MUC5B, 11p11.2-OR4C45 15q11.2-POTEB and 20p11.21-q11.21-MIR663AHG). We found also two regions deleted in both groups (11q14.3-MRE11A and 16q24.2-FANCA).
PD-L1 expression in the two SC clusters. As smoking history has been associated with greater PD-L1 expression in lung cancer and greater efficacy of anti-PD1 immune-checkpoint inhibitors, we examined PD-L1 expression in the two SC clusters with different mutational signatures ( Figure 2D ). PD-L1-positive tumors were more frequent in C sig4 (67%, n ¼ 6/9) versus C sig2-3-13 (17%, n ¼ 1/6), although this difference did not reach statistical significance (P ¼ 0.12).
Clinical features of the clusters. While the C sig2-3-13 patients tended to be more frequently women and older (supplementary Table S1 , available at Annals of Oncology online), the clusters did not differ for other clinical characteristics, including smoking exposure. We found that C sig4 patients had poorer overall survival (OS) and disease-free survival (DFS) compared with C sig2-3-13 patients ( Figure 2B and C) . The median OS in C sig4 was 7.3 months [95% confidence interval (CI): 2.7-29.7], unreached in C sig2-3-13 (log-rank P ¼ 0.001). The median DFS in C sig4 was 2.7 months (95% CI: 0.1-8.8) versus 45.0 months in C sig2-3-13 (95% CI: 40.6-unreached) (log-rank P ¼ 0.003). Since the clinical data of the Liu et al. series [7] was unavailable, we could not confirm the prognostic impact of this molecular classification.
Intratumor heterogeneity in SC
Given that SC presents two different cellular populations, both mesenchymal and epithelial, we sought to characterize this intratumor heterogeneity at a genomic level. We used two different algorithms to decipher the clonal architecture from a unique specimen. The estimated proportion of subclonal population was <10% for all SC cases, clearly supporting the hypothesis of there being a common ancestor (or origin) of the different cellular populations (supplementary Figure S7 , available at Annals of Oncology online). The most frequent driver mutations were primarily found in the major clone, with few exceptions. We found that the MET amplification in sample 13 was subclonal ( Figure 3A) . We examined the tissue sample using MET chromogenic in situ hybridization ( Figure 3B ), confirming the subclonal MET amplification as present within only the sarcoma-like component ( Figure 3C and D) , not the epithelial component ( Figure 3E and F) .
Discussion
We evidenced intertumor molecular variability in SC, proving the existence of two distinct clusters based on mutational
Cluster 1 (C1) Sample  S1  S2  S3  S4  S5  S6  S8  S9  S10 Liu.S4 Liu.S13 Liu.S14 Liu.S23 Liu.S3 S7 S11 S12 S13 S14 S15 Liu.S2 Liu.S5 Liu.S10 Liu.S16 Liu.S25 signatures. This molecular variability is reinforced by the spectrum of altered genes and significantly differing PD-L1 expression between the two clusters. Furthermore, we observed high clinical difference between the clusters in terms of DFS and OS. Unfortunately, patient follow-up was not available for the Liu et al. series, and this latter finding thus remains unconfirmed. We are aware that our conclusions are limited by the study's small sample size. Nevertheless, we were able to confirm intertumor molecular variability in the series of Liu et al. [7] . Though all our patients were current or past smokers, the tobacco-related signature 4 was the predominant signature in only 10 of the 15 cases. The tobacco-related signature 4 is predominantly composed of C>A/G>T transversions, likely due to guanine adducts of benzo [a] pyrene, a component of tobacco smoke [22] , suggesting that smoking directly influences the occurrence of C sig4 tumors. This hypothesis was confirmed by both the C>A/G>T transcription asymmetry and the larger proportion of signature 4 in the clonal mutations, compared with the subclonal. Furthermore, the C sig4 tumors had frequent RAS mutations and strong PD-L1 expression. This suggests that there is great potential of PD-1/PD-L1 immune checkpoint inhibitors in this cluster.
In C sig2-3-13 , the characteristic signatures were 2 and 13, related to APOBEC activation, and signature 3, related to deficient homologous recombination. Signature 16 was also identified in C sig2-3-13 , potentially defining a subgroup of C sig2-3-13 , though a larger series would be needed to confirm this. Signature 3 has been associated with defective homologous recombination, such as in BRCA1 and BRCA2 mutated breast, ovarian, and pancreatic cancers [11] . Interestingly, two-hit BRCA1 and BRCA2 genes . In this section, the mean MET and CEN7 copy numbers were 8 and 4, respectively (ratio MET/CEN7 ¼ 2). (E) Poorly differentiated epithelial component (HES Â400 magnification) with (F) its respective and corresponding SISH MET (Â630 magnification). In this section, the mean MET and CEN7 copy numbers were 6 and 4, respectively (ratio ¼ 1.5).
were observed in three cases of our series presenting signature 3. Signatures 2 and 13 have been attributed to cytosine deamination related to the different APOPEC protein family [23] . These proteins have been reported as playing a role in the carcinogenesis of many cancers, including lung cancer [24, 25] . APOBEC activation can be detected during the early steps of lung tumorigenesis, potentially due to germline variations [26] , as well as in late steps of tumorigenesis specifically in tobacco-related lung cancer [25] . This suggests that tobacco has a different effect over time. In our study, the APOBEC activation signature was present in clonal and subclonal mutations, suggesting a continuous process in the carcinogenesis of these subgroups of SC. Alexandrov et al. reported increased signatures 2 and 13 in smokers lung adenocarcinomas [21] , suggesting that tobacco might trigger mutagenesis through an APOBEC activation, which is consistent with our study.
The different mutational processes also translated into different gene targets. RAS and MAP2K1 mutations were more specific to C sig4 , consistent with the associated KRAS mutations and signature 4 in lung adenocarcinomas. MET alterations, recently associated with SC [7] and more rarely with adenocarcinomas [8] , occurred specifically in $50% of the C sig2-3-13 tumors. The difference in MET alteration prevalence reported in different published series could be due to variable proportions of C sig4 and C sig2-3-13 tumors. In C sig2-3-13 , putative drug target alterations were not limited to MET, also found for EGFR and ERBB2. Moreover, BRCA1 and BRCA2 alterations were also identified, suggesting the therapeutic potential of PARP inhibitors for these tumors. Furthermore, as far as we know, this is the first report of IDH1 mutations in SC. We sequenced an additional series of 70 formalin-fixed paraffin-embedded SC samples using the Cancer Hotspot Panel (Thermofisher), finding two supplementary activating IDH1 R132 mutations co-occurring with KRAS or NRAS mutation (data not shown), leading to a prevalence of 3/95 (3.2%) of SC cases. IDH1 mutations are oncogenic drivers in low-grade gliomas and have also been described in acute myeloid leukemia, thyroid carcinoma, cholangiocarcinoma, chondrosarcoma, and melanoma [27] . In melanoma, IDH1 mutations coexisted with BRAF, NRAS, and KIT mutations, increasing tumor cell growth [28] . Since IDH1 mutations can be targeted, this subject merits attention and further investigation.
In contrast to the high intertumor molecular variability, we found limited intratumor heterogeneity regarding principal oncogenic drivers, which is consistent with previous studies in lung adenocarcinomas [29] . These findings are consistent with our previous results, proving that SC evolves from a common ancestral clone [9] . It is worth noting that this study was not designed to detect subclonal variants with low-allele variations and that we did not perform multiregion sequencing. Moreover, the intertumor heterogeneity might rely on other aspects of tumor biology such as epigenetic changes or gene expression. Such studies might offer better understanding of the mechanisms underlying the specific patterns of SC differentiations. It is already well-established that the sarcoma-like component is derived from the epithelial cells following specific transformations, usually called epithelial-to-mesenchymal transition (EMT) [30, 31] . The transformation of ALKadenocarcinoma to SC at resistance to crizotinib clearly illustrates that SC might derive from EMT of an epithelial tumor [32] . Supporting this observation, we found one tumor exhibited MET amplification specifically in its sarcomatoid component. Although MET activation might have played a role in this specific SC, larger series did not found overall association of MET overexpression with sarcomatoid components [8, 9] .
Conclusion
We described a molecular classification of SC in two clusters, indicating that this tumor type presents intertumor molecular variability. One cluster exhibited mutagenesis directly triggered by tobacco use, frequent RAS mutations, and frequent PD-L1 positivity. In the second cluster, mutagenesis was possibly related to indirect effects of tobacco or other unknown factors, and diverse and frequent targetable genetic alterations were observed. These findings could encourage physicians to conduct broad genetic and immunological testing in SC patients beyond MET exon 14 deletions.
